SV Health Investors Announces the Appointment of Megan MacDonagh

in SV News

Boston, MA & London, UK (September 29, 2020) – SV Health Investors (SV), a leading transatlantic venture capital and growth equity firm, is pleased to welcome Megan MacDonagh to the MedTech Convergence Fund (MCF) team as an Associate. Working closely with the senior investment team, Megan’s role will contribute to the sourcing and evaluation of potential investment opportunities made through the MCF, SV’s first fund focused solely on accelerating early-stage healthcare services, medical products and digital health companies. The MCF mission is to create and invest in novel therapeutic and monitoring technologies that enable superior patient outcomes in lower cost settings and improve healthcare efficiency. Megan’s contributions will accelerate deal execution and support all aspects of both the investment process and portfolio management.

Paul LaViolette, SV Managing Partner on the MCF Team said: “It is fantastic to welcome Megan to the team. Her expertise and entrepreneurial spirit will be of enormous benefit to MCF and SV as we continue our mission to invest in novel technologies and create great companies.”

Megan MacDonagh said “I am delighted to join SV and the MedTech Convergence Fund investment team at such a transformative time in healthcare. This year has shown us all that healthcare delivery can be done differently and that change can happen quickly when the need is clear. I look forward to finding and supporting fantastic teams with the right technologies to truly impact the lives of patients.”

Megan joins SV from Charles River Associates, where as a Senior Life Sciences Consultant, she led strategic projects for top biopharma and MedTech clients across a wide range of therapeutic areas. Prior to joining Charles River Associates, Megan spent six years at Novate Medical (acquired by BTG) in Galway, Ireland developing novel vascular devices from design to FDA approval. During business school, Megan did an internship with The Foundry and Lightstone Ventures in Menlo Park, where she evaluated device and drug/device combination products.

Megan has an MBA from Harvard Business School and received her BE in Biomedical Engineering from the National University of Ireland, Galway.

About SV Health Investors
SV Health Investors is a leading healthcare fund manager committed to investing in tomorrow’s healthcare breakthroughs. SV invests across stages, geographic regions, and sectors, with expertise spanning biotechnology, dementia, healthcare growth, healthcare technology and public equities. With approximately $2.2B in assets under management and a truly transatlantic presence with offices in Boston and London, SV has built an extensive network of talented investment professionals and experienced industry veterans. Since its founding in 1993, SV has invested in more than 175 companies with more than 75 of these having achieved successful acquisitions or IPOs.

About the Medtech Convergence Fund
The Medtech Convergence Fund (MCF) is a seed and early-stage venture capital fund committed to helping entrepreneurs, healthcare professionals and inventors build innovative medical technology companies. Our fund strategy is focused on the increasing convergence of medical technology with software, telecommunications, and new service models to create solutions to some of the most significant health challenges. MCF’s mission is to invest in therapeutic and monitoring technologies that offer superior patient outcomes, while enabling better healthcare efficiency. The MCF team leverages decades of medtech investing and operating experience to help entrepreneurs succeed from the earliest phases of product development. To learn more visit www.medtechconvergence.com.